Publications by authors named "R Orme"

The concept of a focused ultrasound study to identify sources of haemodynamic instability has revolutionized patient care. Point-of-care ultrasound (POCUS) using transthoracic scanning protocols, such as FUSIC Heart, has empowered non-cardiologists to rapidly identify and treat the major causes of haemodynamic instability. There are, however, circumstances when a transoesphageal, rather than transthoracic approach, may be preferrable.

View Article and Find Full Text PDF

Ticagrelor has multiple indications, including for some patients with chronic coronary syndromes (CCS) at high risk of ischaemic events. Body mass can potentially affect pharmacodynamics (PD) and pharmacokinetics (PK). We investigated the influence of body mass (range 53-172 kg, 20.

View Article and Find Full Text PDF

The characteristics of a material's surface are extremely important when considering their interactions with biological species. Despite surface chemistry playing a critical role in mediating the responses of cells, there remains no single rule which dictates absolute performance; this is particularly challenging when considering the response of differing cell types to a range of materials. Here, we highlight the functional behavior of neural stem cells presented as neurospheres, with respect to a range of alkane-based self-assembled monolayers presenting different functional groups: OH, COH, NH, phenyl, CH, SH, and laminin.

View Article and Find Full Text PDF

A novel enoxaparin regimen consisting of intra-arterial bolus (0.75 mg/kg) followed by intravenous infusion (0.75 mg/kg/6 hours) has been developed as a possible solution to the delayed absorption of oral P2Y inhibitors in opiate-treated ST-elevation myocardial infarction (STEMI) patients undergoing primary angioplasty.

View Article and Find Full Text PDF
Article Synopsis
  • Myocardial dysfunction is prevalent in sepsis, but a study called the LeoPARDS trial found that the inodilator levosimendan does not improve organ dysfunction or reduce mortality in septic shock patients.
  • The research measured cardiac biomarkers and inflammatory mediators in patients to assess the drug's effects, revealing no benefits in reducing the SOFA score or 28-day mortality rates.
  • Specifically, patients with high NT-proBNP who received levosimendan showed worse SOFA scores compared to those on placebo, indicating that levosimendan added to standard care does not enhance outcomes in septic patients with cardiac dysfunction.
View Article and Find Full Text PDF